Viatris Inc (VTRS)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $23.87B
Last updated: Nov 17, 2026 at 11:05 AM ET
Viatris Inc (VTRS) Stock Forecast
Analysts expect Viatris (VTRS) to earn $2.59 per share in the fiscal year ending Dec 31, 2026, on revenue of $14.80B. Of 12 analysts, 7 rate the stock Buy or Strong Buy, 4 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 2.50, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 58% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 8.3% |
| Buy | 6 | 50.0% |
| Hold | 4 | 33.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 8.3% |
- Consensus
- Hold
- Total analysts
- 12
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 5.4% and revenue estimates rise 2.8%.
- Fiscal year ending Dec 31, 2026
- $2.59
- EPS consensus, revenue $14.80B
- Fiscal year ending Dec 31, 2027
- $2.73
- EPS consensus, revenue $15.21B
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.59 | $2.56 to $2.62 | 7 | $14.80B | $14.73B to $14.93B | 9 |
| Dec 31, 2027 | $2.73 | $2.63 to $2.86 | 9 | $15.21B | $14.95B to $15.32B | 7 |
Quarterly Estimates
The EPS consensus rises from $0.62 for the quarter ending Dec 31, 2026 to $0.63 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.62 | $0.56 to $0.66 | 12 | $3.84B | $3.64B to $3.99B | 11 |
| Mar 31, 2027 | $0.63 | $0.58 to $0.68 | 6 | $3.60B | $3.53B to $3.67B | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 13 upward and 4 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 0 |
| Fiscal year ending Dec 31, 2027 | 7 | 2 |
| Quarter ending Mar 31, 2027 | 3 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 4.4% from $2.48.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $2.59 | $2.51 | $2.52 | $2.50 | $2.48 | +4.5% |
| Fiscal year ending Dec 31, 2027 | $2.73 | $2.68 | $2.67 | $2.67 | $2.66 | +2.4% |
| Quarter ending Mar 31, 2027 | $0.63 | $0.64 | $0.62 | $0.60 | $0.60 | +6.2% |
Frequently Asked Questions About VTRS
What is the VTRS stock forecast?
Consensus analyst estimates put Viatris's EPS at $2.59 for the fiscal year ending Dec 31, 2026, on revenue of $14.80B. The consensus rating from 12 analysts is Hold.
How do analysts rate VTRS stock?
Of 12 analysts covering Viatris, 1 rates it Strong Buy, 6 Buy, 4 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from VTRS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.59, with estimates from $2.56 to $2.62 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $2.73, with estimates from $2.63 to $2.86 from 9 analysts.
What revenue do analysts expect from Viatris next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $14.80B, with estimates from $14.73B to $14.93B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $15.21B, with estimates from $14.95B to $15.32B.
How many analysts cover VTRS?
12 analysts rate Viatris stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
VTRS pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts